Approach
SNIPR is making CRISPR-based precision medicines to target the world’s superbugs
A silent pandemic of antimicrobial resistant (AMR) bacterial pathogens is on the rise and we risk living in a future where antibiotics are no longer effective.
SNIPR is making precision medicines to target these harmful bacteria. The majority of bacteria living within your body are good, so we only want to remove the harmful ones.
Our CRISPR technology is designed to function exclusively in bacteria and by programming our proprietary CRISPR platform, we can very precisely find and cut specific DNA in the target bacteria of our choice to kill those and leaving the good bacteria untouched.
We deliver our CRISPR precision cargo by two complementary delivery vehicles, either phages, which are viruses that only kill bacteria or via good bacteria that we engineer to transfer our CRISPR-cargo to the target bacteria. We are world-leading in CRISPR-arming and engineering both phages and the good bacteria to become efficient bacterial killers.
Our CRISPR and delivery platforms have been validated by our strong collaborations and are agnostic to any antibiotic resistance carried by the bacteria. The platforms are therefore well suited to tackle the global AMR crisis.
We are currently applying our platform technology to target critical pathogens and antimicrobial resistances that are also at the top of recent pathogen priority lists by WHO and CDC.